Abbott mechanical heart valves deliver exceptional hemodynamics and performance while maintaining low complication rates over the long term.

DEMONSTRATED SAFETY OVER NOTABLY LONG-TERM STUDIES

The Abbott mechanical heart valves have demonstrated low mortality and a low incidence of valve-related events over a period of at least 30 years.1,2

SAITO3

 Aortic Valve ReplacementMitral Valve Replacement
Retrospective Study950 patients, 30 years1,255 patients, 30 years
Thromboembolism0.56%/pt-year0.99%/pt-year
Thrombosis0.02%/pt-year0.03%/pt-year
Bleeding Event0.27%/pt-year0.43%/pt-year

Read the Saito abstract

JOHNSON4

 Aortic Valve ReplacementMitral Valve Replacement
Retrospective Study584 patients, 30 years439 patients, 30 years
Thromboembolism1.7%/pt-year2.9%/pt-year
Thrombosis*0.2%/pt-year0.1%/pt-year
Bleeding Event2.4%/pt-year2.0%/pt-year

*Calculated values.

Read the Johnson abstract

AORTIC ANTICOAGULATION MANAGEMENT
A DEMONSTRATED WORLDWIDE HISTORY OF EXCELLENCE OVER A WIDE INR RANGE
 

Click to read the abstracts:    SAITO    LOWERING-IT   ESCAT III   EMERY


*44/197 patients in the Lowering-IT study were implanted with Abbott Valves.
**This was further stratified into a control group, a very low INR (monitored 1x weekly), and a very low INR (monitored 2x weekly) group.
***Thromboembolic events for VL1 and VL2 groups are listed together, respectively.
†Bleeding events for VL1 and VL2 groups are listed together, respectively.

MAT-2010509 v1.0 | Item approved for Global OUS use.

References
  1. Saito S, Tsukui H, Iwasa S, et al. Bileaflet mechanical valve replacement: An assessment of outcomes with 30 years of follow-up. Interact Cardiovasc Thorac Surg. 2016;23(4):599-607. doi: 10.1093/icvts/ivw196
  2. Johnson S, Stroud MR, Kratz JM, et al. Thirty-year experience with a bileaflet mechanical valve prosthesis. J Thorac Cardiovasc Surg. 2018;157(1):213-222. doi: 10.1016/j.jtcvs.2018.09.002
  3. Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis-patient mismatch in the aortic valve position and its prevention. J Am Coll Cardiol. 2000;36(4):1131-1141. doi.org/10.1016/s0735-1097(00)00859-7
  4. Bach DS, Sakwa MP, Goldbach M, et al. Hemodynamics and early clinical performance of the St. Jude Medical Regent mechanical aortic valve. Ann Thorac Surg. 2002;74(6):2003-2009. 
  5. Torella M, Torella D, Chiodini P, et al. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the "LOWERING-IT" Trial. Am Heart J. 2010;160(1); 171-178. doi: 10.1016/j.ahj.2010.05.005
  6. Koertke H, Zittermann A, Wagner O, et al. Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement. Ann Thorac Surg. 2010;90(5):1487-1493.
  7. Emery RW, Krogh CC, Arom KV, et al. The St. Jude Medical cardiac valve prosthesis: a 25-year experience with single valve replacement. Ann Thorac Surg. 2005;79(3):776-82. doi: 10.1016/j.athoracsur.2004.08.047

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.

Ok

Sign up

Receive updates from Abbott Structural Heart

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

YOU ARE ABOUT TO LEAVE
www.structural­heart­solutions.com

You are now leaving www.structuralheartsolutions.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.